medigraphic.com
ISSN 1527-3172 (Digital)

2017, Número 4

<< Anterior Siguiente >>

MEDICC Review 2017; 19 (4)


Biosimilars and the real world

Ledón NN, Lage DA

Idioma: Ingles.
Referencias bibliográficas: 33
Paginas: 9-14
Archivo PDF: 107.74 Kb.


FRAGMENTO

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Schellekens H. When biotech proteins go offpatent. Trends Biotechnol. 2004 Aug;22(8):406–10.

  2. EvaluatePharma®. World Preview 2016, Outlook to 2022. 9th ed [Internet]. Boston: Evaluate Pharma; 2016 Sep [cited 2017 Mar 12]. Available from: http://info.evaluategroup.com/rs/607 -YGS-364/images/wp16.pdf

  3. Giezen T, Avendaño-Solá C, Annese V, Wolff- Holz E, Weise M, Ekman N, et al. Roundtable on biosimilars with European regulators and medical societies, Brussels, Belgium, 12 January 2016. GaBI J. 2016 May 4;5(2):74–83.

  4. Evens RP. Pharma Success in Product Development— Does Biotechnology Change the Paradigm in Product Development and Attrition. AAPS J. 2016 Jan;18(1):281–5.

  5. World Trade Organization [Internet]. Geneva: World Trade Organization; c2017. Temas Comerciales. Las patentes de productos farmacéuticos y el Acuerdo sobre los ADPIC; 2006 Sep [cited 2017 Sep 4]; [about 6 screens]. Available from: https://www.wto.org/spanish/tratop_s/trips_s/ pharma_ato186_s.htm. Spanish.

  6. Food and Drug Administration [Internet]. Washington, D.C.: Food and Drug Administration; c2017. FDA: History; [cited 2017 Mar 12]; [about 2 screens]. Available from: https://www.fda.gov/ AboutFDA/WhatWeDo/History/default.htm

  7. Löbenberg R, Amidon GL. Modern bioavailability, bioequivalence and biopharmaceutics classifi cation system. New scientifi c approaches to international regulatory standards. Eur J Pharm Biopharm. 2000 Jul;50(1):3–12.

  8. Chen ML, Shah V, Patnaik R, Adams W, Hussain A, Conner D, et al. Bioavailability and bioequivalence: an FDA regulatory overview. Pharm Res. 2001 Dec;18(12):1645–50.

  9. Mossinghoff GJ. Overview of the Hatch-Waxman act and its impact on the drug development process. Food Drug Law J. 1999;54(2):187–94.

  10. U.S Food and Drugs Administration [Internet]. Washington, D.C.: Food and Drugs Administration; c2017. Drugs. The Generic Drug Approval Process; 2016 Jun [cited 2017 Mar 12]; [about 2 screens]. Available from: https://www.fda.gov/ Drugs/NewsEvents/ucm508150.htm

  11. Price WN, Rai AK. Manufacturing barriers to biologics competition and innovation. Iowa Law Rev. 2016;101(3):1023–63.

  12. U.S Food and Drugs Administration [Internet]. Washington, D.C.: Food and Drugs Administration; c2017. Number of FDA new molecular entities approved from 1940–2015 with linear trendline. FDA (1940–2011); [updated 2013 Jan 18; cited 2017 Mar 12]; [about 3 screens]. Available from: http://www.fda.gov/aboutfda/ whatwedo/history/productregulation/summaryof ndaapprovalsreceipts1938tothepresent/default .htm

  13. Mullard A. 2014 FDA drug approvals. Nat Rev Drug Discov [Internet]. 2015 Feb [cited 2017 Mar 12];14(2):77–81. Available from: http:// www.nature.com/nrd/journal/v14/n2/full/nrd4545 .html?foxtrotcallback=true

  14. Legal Information Institute [Internet]. New York: Cornell Law School; c2017. U.S Code. 42 U.S. Code § 262—Regulation of biological products; [cited 2017 Mar 12]. Available from: https://www .law.cornell.edu/uscode/text/42/262

  15. Combest AJ, Wang S, Healey BT, Reitsma DJ. Alternative statistical strategies for biosimilar drug development. GaBI J. 2014;3(1):13–20.

  16. European Medicines Agency [Internet]. London: European Medicines Agency; c1999–2017. European public assessment reports; [updated 2016 Oct; cited 2017 Mar 12]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl =pages/medicines/landing/epar_search .jsp&mid=WC0b01ac058001d125

  17. U.S Food and Drugs Administration. Considerations in Demonstrating Interchangeability with a Reference Product [Internet]. Washington, D.C.: Food and Drugs Administration; 2017 Jan [cited 2017 Mar 12]. 27 p. Available from: https://www .fda.gov/downloads/Drugs/GuidanceComplian ceRegulatoryInformation/Guidances/UCM 537135.pdf

  18. McCamish M, Woollett G. Worldwide Experience with Biosimilar Development. MAbs [Internet]. 2011 Mar–Apr;3(2):209–17. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC3092622/

  19. Schneider CK. Biosimilars in rheumatology: the wind of change. Ann Rheum Dis. 2013 Mar;72(3):315–8.

  20. Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol. 2011 Apr;29(4):310–2.

  21. Louët S. Lessons from Eprex for biogeneric fi rms. Nat Biotechnol. 2003 Sep;21(9):956–7.

  22. Cameron F, McCormack PL. Obinutuzumab: fi rst global approval. Drugs. 2014 Jan;74(1):147–54.

  23. Cavalli F. An appeal to world leaders: stop cancer now. Lancet. 2013 Feb 9;381(9865):425–6.

  24. World Health Organization [Internet]. Geneva: World Health Organization; c2017. Media Centre. News release. WHO to begin pilot prequalifi cation of biosimilars for cancer treatment; 2017 May 4 [cited 2017 Jun 10]; [updated 2017 Aug]. Available from: http://www.who.int/mediacentre/ news/releases/2017/pilot-prequalification -biosimilars/en/

  25. Henry D, Taylor C. Pharmacoeconomics of cancer therapies: considerations with the introduction of biosimilars. Semin Oncol. 2014 Apr;41 Suppl 3:S13–20.

  26. Aapro M, Cornes P, Sun D, Abraham I. Comparative cost effi ciency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer. Ther Adv Med Oncol. 2012 May;4(3):95–105.

  27. Abraham I, Han L, Sun D, MacDonald K, Aapro M. Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries. Future Oncol. 2014;10(9):1599–609.

  28. Ebbers HC, Muenzberg M, Schellekens H. The safety of switching between therapeutic proteins. Expert Opin Biol Ther. 2012 Nov;12(11):1473–85.

  29. GaBI Online [Internet]. Mol (BE): Generics and Biosimilar Initiative; Huge discount on biosimilar infl iximab in Norway; 2015 Mar 13 [cited 2017 Mar 12]. Available from: http://www.gabionline.net/Biosimilars/General/Huge-discount-on -biosimilar-infl iximab-in-Norway

  30. Medicines for Europe. Memo. Positioning Statements on Physician-led Switching for Biosimilar Medicines [Internet]. Brussels: Medicines for Europe; 2017 Jun [cited 2017 Jun 25]. 20 p. Available from: http://www.medicinesforeurope.com/ wp-content/uploads/2017/03/M-Biosimilars-Over view-of-positions-on-physician-led-switching.pdf

  31. Lage A. Global pharmaceutical development and access: critical issues of ethics and equity. MEDICC Rev. 2011 Jul;13(3):16–22.

  32. Lage A. Connecting science to population health: the “closed loop” approach. MEDICC Rev. 2007 Oct;9(1):48.

  33. Markus R, Liu J, Ramchandani M, Landa D, Born T, Kaur P. Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confi dence for the Healthcare Community. BioDrugs. 2017 Jun;31(3):175–87.




2020     |     www.medigraphic.com